Disilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B., Oaknin, A., et al. (2023). Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. OBSTETRICAL & GYNECOLOGICAL SURVEY, 78(1), 25-27 [10.1097/OGX.0000000000001120].

Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Colombo N.
Primo
;
2023

Editoriale, introduzione, contributo a forum/dibattito
BRCA1 protein; BRCA2 protein; olaparib; placebo
English
9-set-2022
2023
78
1
25
27
none
Disilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B., Oaknin, A., et al. (2023). Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. OBSTETRICAL & GYNECOLOGICAL SURVEY, 78(1), 25-27 [10.1097/OGX.0000000000001120].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/569662
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 5
Social impact